{"gene":"LGALS2","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":2004,"finding":"Galectin-2 (LGALS2) directly binds lymphotoxin-alpha (LTA) protein, and a functional SNP in LGALS2 affects its transcriptional level in vitro, leading to altered LTA secretion. Both galectin-2 and LTA are co-expressed in smooth muscle cells and macrophages in human atherosclerotic lesions, placing galectin-2 in the LTA inflammatory cascade relevant to myocardial infarction pathogenesis.","method":"Protein-protein binding assay (galectin-2/LTA interaction), in vitro transcriptional reporter assay for SNP effect on LGALS2 expression, immunohistochemistry for co-localization in atherosclerotic tissue","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — direct binding assay plus functional in vitro transcriptional assay, published in high-impact journal with 199 citations","pmids":["15129282"],"is_preprint":false},{"year":2022,"finding":"Tumor cell-intrinsic Lgals2 promotes an immunosuppressive microenvironment in triple-negative breast cancer by inducing increased numbers of tumor-associated macrophages and driving their M2-like polarization and proliferation through the CSF1/CSF1R signaling axis. Blockade of LGALS2 with an inhibitory antibody arrested tumor growth and reversed immune suppression.","method":"In vivo CRISPR screens in multiple mouse TNBC models, transcriptomic analysis, functional antibody blockade, macrophage polarization assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 — in vivo CRISPR functional screening plus mechanistic follow-up with antibody blockade and transcriptomic validation across multiple models","pmids":["35767614"],"is_preprint":false},{"year":2020,"finding":"Galectin-2 (Gal2/LGALS2) suppresses colon tumor growth by inhibiting STAT3 phosphorylation. Gal2 overexpression in human colon tumor epithelial cells decreased proliferation and blunted H2O2-induced STAT3 phosphorylation, while Gal2-KO mice developed significantly larger tumors with markedly increased STAT3 phosphorylation compared to wild-type. Additionally, Gal2 deficiency ameliorated DSS-induced acute colitis, indicating a role in regulating oxidative stress responses in the colon.","method":"Genome-wide CRISPR knockout screen (NGS), Lgals2 knockout mouse model (DSS colitis and AOM/DSS tumorigenesis), LGALS2 overexpression and knockdown in human colon cancer cells, Western blot for STAT3 phosphorylation, CCK-8 proliferation assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — genome-wide CRISPR screen confirmed by in vivo KO mouse model and in vitro gain/loss-of-function with defined molecular readout (STAT3 phosphorylation)","pmids":["33110234"],"is_preprint":false},{"year":2022,"finding":"LGALS2 suppresses papillary thyroid carcinoma (PTC) cell proliferation and promotes apoptosis via activation of the PI3K/AKT pathway. LGALS2 knockdown enhanced PTC cell proliferative activity and reduced apoptotic sensitivity, while LGALS2 overexpression had the opposite effect both in vitro and in a murine xenograft model.","method":"LGALS2 overexpression (pcDNA4.0 vector) and siRNA knockdown in PTC cell lines, CCK-8 assay, EdU uptake assay, apoptosis assay, murine xenograft model, Western immunoblotting for PI3K/AKT pathway components","journal":"Gland surgery","confidence":"Medium","confidence_rationale":"Tier 2/3 — in vitro and in vivo gain/loss-of-function with pathway readout, but from a single lab with limited mechanistic depth on PI3K/AKT mechanism","pmids":["36221286"],"is_preprint":false}],"current_model":"LGALS2 encodes galectin-2, a beta-galactoside-binding lectin that directly binds lymphotoxin-alpha (LTA) to modulate inflammatory signaling relevant to myocardial infarction; in cancer contexts, it suppresses tumor growth by inhibiting STAT3 phosphorylation in colon cancer and activating the PI3K/AKT pathway in thyroid cancer, while in triple-negative breast cancer it promotes immune evasion by driving M2-like macrophage polarization and proliferation through the CSF1/CSF1R axis."},"narrative":{"teleology":[{"year":2004,"claim":"The first mechanistic link for galectin-2 was established by showing it directly binds lymphotoxin-alpha and that a cis-regulatory SNP modulates LGALS2 transcription, thereby altering LTA secretion and connecting galectin-2 to inflammatory vascular disease.","evidence":"Protein–protein binding assay, in vitro transcriptional reporter assay for SNP effect, and immunohistochemistry co-localization in human atherosclerotic lesions","pmids":["15129282"],"confidence":"High","gaps":["Structural basis of the galectin-2–LTA interaction is undefined","Whether galectin-2/LTA binding is carbohydrate-dependent or protein–protein mediated is not resolved","Causal role in atherosclerosis progression not tested by genetic intervention in vivo"]},{"year":2020,"claim":"A direct tumor-suppressive mechanism was identified: galectin-2 inhibits STAT3 phosphorylation in colonic epithelial cells, and Lgals2-knockout mice develop significantly larger colon tumors with hyperactivated STAT3, establishing galectin-2 as a negative regulator of STAT3 signaling in colorectal tumorigenesis.","evidence":"Genome-wide CRISPR screen, Lgals2-knockout mouse model with AOM/DSS-induced tumors, and overexpression/knockdown in human colon cancer cells with phospho-STAT3 readout","pmids":["33110234"],"confidence":"High","gaps":["Whether galectin-2 directly binds STAT3 or acts via an upstream mediator is unknown","The opposing effect of Gal2 deficiency in colitis versus tumorigenesis is mechanistically unresolved","Relevance of the LTA-binding function to the colon tumor context not examined"]},{"year":2022,"claim":"Two studies expanded the cancer biology of galectin-2 in opposite directions: in triple-negative breast cancer, tumor-derived LGALS2 promotes immunosuppression by driving M2-like macrophage polarization via CSF1/CSF1R signaling, while in papillary thyroid carcinoma, LGALS2 suppresses proliferation and induces apoptosis through PI3K/AKT pathway activation.","evidence":"In vivo CRISPR screens in multiple mouse TNBC models with antibody blockade and transcriptomic validation [PMID:35767614]; overexpression/knockdown in PTC cell lines with xenograft confirmation and PI3K/AKT immunoblotting [PMID:36221286]","pmids":["35767614","36221286"],"confidence":"High","gaps":["The direct receptor or binding partner mediating CSF1/CSF1R axis activation by galectin-2 is unidentified","PI3K/AKT activation mechanism by galectin-2 in thyroid cancer is characterized only at the pathway level without a defined molecular target","How galectin-2 exerts pro-tumorigenic effects in breast cancer but anti-tumorigenic effects in colon and thyroid cancer is not reconciled"]},{"year":null,"claim":"The molecular basis for galectin-2's context-dependent tumor-promoting versus tumor-suppressive activities remains unresolved, and no unifying model connects its lectin-binding properties to the distinct downstream pathways (STAT3, PI3K/AKT, CSF1/CSF1R) engaged in different tissues.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural data for galectin-2 in complex with any signaling partner","Whether carbohydrate recognition is required for each downstream signaling outcome has not been tested","No integrative study has compared galectin-2 interactomes across tissue types"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,2,3]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,3]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,2,3]}],"complexes":[],"partners":["LTA","CSF1R","STAT3"],"other_free_text":[]},"mechanistic_narrative":"Galectin-2 (LGALS2) is a β-galactoside-binding lectin that functions as an immunomodulatory and tumor-regulatory protein across multiple tissue contexts. It directly binds lymphotoxin-alpha (LTA) in vascular smooth muscle cells and macrophages within atherosclerotic lesions, linking it to inflammatory signaling in myocardial infarction pathogenesis [PMID:15129282]. In colon cancer, galectin-2 suppresses tumor growth by inhibiting STAT3 phosphorylation, as demonstrated by enlarged tumors with elevated phospho-STAT3 in Lgals2-knockout mice [PMID:33110234], while in triple-negative breast cancer it drives an immunosuppressive microenvironment by promoting M2-like macrophage polarization and proliferation through the CSF1/CSF1R axis, and antibody-mediated blockade of LGALS2 reverses this immune evasion and arrests tumor growth [PMID:35767614]."},"prefetch_data":{"uniprot":{"accession":"P05162","full_name":"Galectin-2","aliases":["Beta-galactoside-binding lectin L-14-II","HL14","Lactose-binding lectin 2","S-Lac lectin 2"],"length_aa":132,"mass_kda":14.6,"function":"This protein binds beta-galactoside. Its physiological function is not yet known","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/P05162/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LGALS2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LGALS2","total_profiled":1310},"omim":[{"mim_id":"608446","title":"MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/608446"},{"mim_id":"600615","title":"LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 7; LGALS7","url":"https://www.omim.org/entry/600615"},{"mim_id":"150571","title":"LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 2; LGALS2","url":"https://www.omim.org/entry/150571"},{"mim_id":"150570","title":"LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 1; LGALS1","url":"https://www.omim.org/entry/150570"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Mitochondria","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"gallbladder","ntpm":315.1},{"tissue":"intestine","ntpm":186.3},{"tissue":"kidney","ntpm":142.2},{"tissue":"pancreas","ntpm":199.3}],"url":"https://www.proteinatlas.org/search/LGALS2"},"hgnc":{"alias_symbol":["HL14"],"prev_symbol":[]},"alphafold":{"accession":"P05162","domains":[{"cath_id":"2.60.120.200","chopping":"6-132","consensus_level":"high","plddt":97.648,"start":6,"end":132}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P05162","model_url":"https://alphafold.ebi.ac.uk/files/AF-P05162-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P05162-F1-predicted_aligned_error_v6.png","plddt_mean":96.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LGALS2","jax_strain_url":"https://www.jax.org/strain/search?query=LGALS2"},"sequence":{"accession":"P05162","fasta_url":"https://rest.uniprot.org/uniprotkb/P05162.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P05162/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P05162"}},"corpus_meta":[{"pmid":"15129282","id":"PMC_15129282","title":"Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro.","date":"2004","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15129282","citation_count":199,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35767614","id":"PMC_35767614","title":"In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35767614","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33110234","id":"PMC_33110234","title":"Genome-wide CRISPR screen identifies LGALS2 as an oxidative stress-responsive gene with an inhibitory function on colon tumor growth.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33110234","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39350165","id":"PMC_39350165","title":"Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients.","date":"2024","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39350165","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26045830","id":"PMC_26045830","title":"PPARG, AGTR1, CXCL16 and LGALS2 polymorphisms are correlated with the risk for coronary heart disease.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26045830","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8449510","id":"PMC_8449510","title":"Two members of the S-lac lectin gene family, LGALS1 and LGALS2, reside in close proximity on human chromosome 22q12-q13.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8449510","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17098239","id":"PMC_17098239","title":"LGALS2 functional variant rs7291467 is not associated with susceptibility to myocardial infarction in Caucasians.","date":"2006","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/17098239","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27014587","id":"PMC_27014587","title":"Genetic association between inflammatory genes (IL-1α, CD14, LGALS2, PSMA6) and risk of ischemic stroke: A meta-analysis.","date":"2016","source":"Meta gene","url":"https://pubmed.ncbi.nlm.nih.gov/27014587","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34371260","id":"PMC_34371260","title":"Gene polymorphisms of LGALS2, LGALS3 and LGALS9 in patients with rheumatoid arthritis.","date":"2021","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34371260","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16468038","id":"PMC_16468038","title":"Genotype of galectin 2 (LGALS2) is associated with insulin-glucose profile in the British Women's Heart and Health Study.","date":"2006","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/16468038","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37838802","id":"PMC_37838802","title":"Investigation of LGALS2 expression in the TCGA database reveals its clinical relevance in breast cancer immunotherapy and drug resistance.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37838802","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36221286","id":"PMC_36221286","title":"LGALS2 suppresses the progression of papillary thyroid carcinoma by regulating the PI3K/AKT pathway.","date":"2022","source":"Gland surgery","url":"https://pubmed.ncbi.nlm.nih.gov/36221286","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22658674","id":"PMC_22658674","title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658674","citation_count":1718,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8063692","id":"PMC_8063692","title":"Galectins. Structure and function of a large family of animal lectins.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8063692","citation_count":1222,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8692888","id":"PMC_8692888","title":"Expression of galectin-3 modulates T-cell growth and apoptosis.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8692888","citation_count":661,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19528259","id":"PMC_19528259","title":"The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.","date":"2009","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19528259","citation_count":547,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33845483","id":"PMC_33845483","title":"Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33845483","citation_count":532,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17110338","id":"PMC_17110338","title":"Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17110338","citation_count":517,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16549783","id":"PMC_16549783","title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16549783","citation_count":513,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21189092","id":"PMC_21189092","title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.","date":"2010","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21189092","citation_count":465,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10925302","id":"PMC_10925302","title":"Human galectin-3 is a novel chemoattractant for monocytes and macrophages.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10925302","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27693506","id":"PMC_27693506","title":"TRIMs and Galectins Globally Cooperate and TRIM16 and Galectin-3 Co-direct Autophagy in Endomembrane Damage Homeostasis.","date":"2016","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/27693506","citation_count":386,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20130888","id":"PMC_20130888","title":"Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.","date":"2010","source":"Clinical research in cardiology : official journal of the German Cardiac Society","url":"https://pubmed.ncbi.nlm.nih.gov/20130888","citation_count":378,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9582341","id":"PMC_9582341","title":"X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9582341","citation_count":356,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7573347","id":"PMC_7573347","title":"Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages.","date":"1995","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7573347","citation_count":340,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29207027","id":"PMC_29207027","title":"Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).","date":"2017","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29207027","citation_count":335,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23403292","id":"PMC_23403292","title":"Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23403292","citation_count":307,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23117656","id":"PMC_23117656","title":"Galectin-3 mediates aldosterone-induced vascular fibrosis.","date":"2012","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23117656","citation_count":286,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15181153","id":"PMC_15181153","title":"NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin.","date":"2004","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/15181153","citation_count":281,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":7054,"output_tokens":1255,"usd":0.019994},"stage2":{"model":"claude-opus-4-6","input_tokens":4472,"output_tokens":1539,"usd":0.091253},"total_usd":0.250922,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":19277,"output_tokens":2209,"usd":0.045483},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":4739,"output_tokens":1564,"usd":0.094192}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"Galectin-2 (LGALS2 protein) directly binds to lymphotoxin-alpha (LTA), and a SNP in LGALS2 affects the transcriptional level of galectin-2 in vitro, leading to altered secretion of LTA and downstream inflammatory signaling relevant to myocardial infarction.\",\n      \"method\": \"Protein binding assay (LTA binds galectin-2), in vitro transcriptional reporter assay, immunohistochemistry showing co-expression of galectin-2 and LTA in atherosclerotic lesions\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding demonstrated, functional transcriptional variant validated in vitro, replicated across multiple analyses in a high-citation foundational paper\",\n      \"pmids\": [\"15129282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Tumor cell-intrinsic Lgals2 promotes M2-like polarization and proliferation of tumor-associated macrophages through the CSF1/CSF1R signaling axis, creating an immunosuppressive tumor microenvironment in triple-negative breast cancer; blockade with an inhibitory antibody arrested tumor growth and reversed immune suppression.\",\n      \"method\": \"In vivo CRISPR screens, transcriptomic analysis, loss-of-function studies in mouse models, inhibitory antibody blockade experiment\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo functional CRISPR screen plus mechanistic follow-up with pathway identification, single lab\",\n      \"pmids\": [\"35767614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Galectin-2 (Gal2/LGALS2) suppresses colon tumor growth by inhibiting STAT3 phosphorylation; Gal2 overexpression decreased proliferation of human colon tumor epithelial cells and blunted H2O2-induced STAT3 phosphorylation, while Gal2-KO mice developed larger tumors with significantly increased STAT3 phosphorylation.\",\n      \"method\": \"Genome-wide CRISPR knockout screen, Lgals2 knockout mouse model (AOM/DSS colorectal cancer model), Gal2 overexpression in vitro, Western blot for pSTAT3\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — orthogonal methods (CRISPR screen, KO mouse, overexpression) with defined molecular readout (STAT3 phosphorylation), single lab\",\n      \"pmids\": [\"33110234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LGALS2 suppresses papillary thyroid carcinoma cell proliferation and promotes apoptosis by activating the PI3K/AKT pathway; LGALS2 knockdown enhanced proliferation and reduced apoptosis sensitivity, while overexpression had the opposite effect both in vitro and in a murine xenograft model.\",\n      \"method\": \"siRNA knockdown, overexpression construct, CCK-8 proliferation assay, EdU uptake assay, apoptosis assay, murine xenograft model, Western immunoblotting for PI3K/AKT pathway components\",\n      \"journal\": \"Gland surgery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays plus in vivo validation, single lab\",\n      \"pmids\": [\"36221286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"LGALS2 (L-14-II) and LGALS1 (L-14-I) were mapped to the q12-q13 region of human chromosome 22, establishing their genomic proximity and suggesting a gene cluster for lactose-binding proteins.\",\n      \"method\": \"Chromosomal mapping (genomics)\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal mapping, replicated by subsequent studies referencing this locus\",\n      \"pmids\": [\"8449510\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LGALS2 encodes galectin-2, a galactose-binding lectin that directly binds lymphotoxin-alpha (LTA) and modulates its secretion, thereby influencing downstream inflammatory signaling; it also suppresses tumor cell proliferation via inhibition of STAT3 phosphorylation and activation of the PI3K/AKT pathway, and in the tumor microenvironment promotes M2-like macrophage polarization through the CSF1/CSF1R axis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEEP papers.\n\n**Classification:**\n\nRetrieved papers:\n1. PMID:15129282 — LGALS2/galectin-2 binds LTA, MI association → **KEEP**\n2. PMID:35767614 — Lgals2 in TNBC, CSF1/CSF1R axis → **KEEP**\n3. PMID:33110234 — LGALS2/Gal2, STAT3, colon cancer → **KEEP**\n4. PMID:39350165 — LGALS2 in TLS/DCs, breast cancer — largely expression/IHC/transcriptomics → **EXCLUDE** (no direct mechanistic experiment)\n5. PMID:26045830 — SNP association study only → **EXCLUDE**\n6. PMID:8449510 — Chromosomal mapping of LGALS1/LGALS2 → **EXCLUDE** (no mechanism)\n7. PMID:17098239 — SNP association replication study → **EXCLUDE**\n8. PMID:27014587 — Meta-analysis of SNPs → **EXCLUDE**\n9. PMID:34371260 — SNP association, RA → **EXCLUDE**\n10. PMID:16468038 — Genetic association, insulin/glucose → **EXCLUDE** (no direct mechanism)\n11. PMID:37838802 — Expression analysis, TCGA → **EXCLUDE**\n12. PMID:36221286 — LGALS2 KO/OE, PI3K/AKT, PTC → **KEEP**\n\nAdditional gene2pubmed papers — most describe galectin-3 (LGALS3), not LGALS2, or are large-scale interactome/proteomics datasets:\n- PMID:8063692 — Galectins family review (not LGALS2-specific mechanism) → **EXCLUDE**\n- PMID:9582341 — Galectin-3 crystal structure → **EXCLUDE** (LGALS3)\n- PMID:8692888 — Galectin-3 T-cell apoptosis → **EXCLUDE** (LGALS3)\n- PMID:16549783 — Galectin-3 fibrosis → **EXCLUDE** (LGALS3)\n- PMID:10925302 — Galectin-3 monocyte chemoattractant → **EXCLUDE** (LGALS3)\n- PMID:7573347 — Galectin-3 monocytes → **EXCLUDE** (LGALS3)\n- PMID:27693506 — TRIM16/Galectin-3 autophagy → **EXCLUDE** (LGALS3)\n- PMID:15181153 — Galectin-3/NG2 angiogenesis → **EXCLUDE** (LGALS3)\n- PMID:23117656 — Galectin-3 vascular fibrosis → **EXCLUDE** (LGALS3)\n- PMID:29207027 — Galectin-3 review → **EXCLUDE** (LGALS3)\n- All interactome/proteomics large-scale papers (BioPlex, HuRI, etc.) — not LGALS2-specific → **EXCLUDE**\n- PMID:21189092, PMID:20130888 — Galectin-3 heart failure biomarker → **EXCLUDE** (LGALS3)\n- PMID:22658674, PMID:12477932, PMID:15489334, PMID:8889548, etc. — genomics/cDNA resource papers → **EXCLUDE**\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"Galectin-2 (LGALS2) directly binds lymphotoxin-alpha (LTA) protein, and a functional SNP in LGALS2 affects its transcriptional level in vitro, leading to altered LTA secretion. Both galectin-2 and LTA are co-expressed in smooth muscle cells and macrophages in human atherosclerotic lesions, placing galectin-2 in the LTA inflammatory cascade relevant to myocardial infarction pathogenesis.\",\n      \"method\": \"Protein-protein binding assay (galectin-2/LTA interaction), in vitro transcriptional reporter assay for SNP effect on LGALS2 expression, immunohistochemistry for co-localization in atherosclerotic tissue\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding assay plus functional in vitro transcriptional assay, published in high-impact journal with 199 citations\",\n      \"pmids\": [\"15129282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Tumor cell-intrinsic Lgals2 promotes an immunosuppressive microenvironment in triple-negative breast cancer by inducing increased numbers of tumor-associated macrophages and driving their M2-like polarization and proliferation through the CSF1/CSF1R signaling axis. Blockade of LGALS2 with an inhibitory antibody arrested tumor growth and reversed immune suppression.\",\n      \"method\": \"In vivo CRISPR screens in multiple mouse TNBC models, transcriptomic analysis, functional antibody blockade, macrophage polarization assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo CRISPR functional screening plus mechanistic follow-up with antibody blockade and transcriptomic validation across multiple models\",\n      \"pmids\": [\"35767614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Galectin-2 (Gal2/LGALS2) suppresses colon tumor growth by inhibiting STAT3 phosphorylation. Gal2 overexpression in human colon tumor epithelial cells decreased proliferation and blunted H2O2-induced STAT3 phosphorylation, while Gal2-KO mice developed significantly larger tumors with markedly increased STAT3 phosphorylation compared to wild-type. Additionally, Gal2 deficiency ameliorated DSS-induced acute colitis, indicating a role in regulating oxidative stress responses in the colon.\",\n      \"method\": \"Genome-wide CRISPR knockout screen (NGS), Lgals2 knockout mouse model (DSS colitis and AOM/DSS tumorigenesis), LGALS2 overexpression and knockdown in human colon cancer cells, Western blot for STAT3 phosphorylation, CCK-8 proliferation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide CRISPR screen confirmed by in vivo KO mouse model and in vitro gain/loss-of-function with defined molecular readout (STAT3 phosphorylation)\",\n      \"pmids\": [\"33110234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LGALS2 suppresses papillary thyroid carcinoma (PTC) cell proliferation and promotes apoptosis via activation of the PI3K/AKT pathway. LGALS2 knockdown enhanced PTC cell proliferative activity and reduced apoptotic sensitivity, while LGALS2 overexpression had the opposite effect both in vitro and in a murine xenograft model.\",\n      \"method\": \"LGALS2 overexpression (pcDNA4.0 vector) and siRNA knockdown in PTC cell lines, CCK-8 assay, EdU uptake assay, apoptosis assay, murine xenograft model, Western immunoblotting for PI3K/AKT pathway components\",\n      \"journal\": \"Gland surgery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — in vitro and in vivo gain/loss-of-function with pathway readout, but from a single lab with limited mechanistic depth on PI3K/AKT mechanism\",\n      \"pmids\": [\"36221286\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LGALS2 encodes galectin-2, a beta-galactoside-binding lectin that directly binds lymphotoxin-alpha (LTA) to modulate inflammatory signaling relevant to myocardial infarction; in cancer contexts, it suppresses tumor growth by inhibiting STAT3 phosphorylation in colon cancer and activating the PI3K/AKT pathway in thyroid cancer, while in triple-negative breast cancer it promotes immune evasion by driving M2-like macrophage polarization and proliferation through the CSF1/CSF1R axis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LGALS2 encodes galectin-2, a β-galactoside-binding lectin that functions both as a modulator of inflammatory signaling and as a tumor suppressor. Galectin-2 directly binds lymphotoxin-alpha (LTA) and regulates its secretion, linking galectin-2 levels to inflammatory cascades in atherosclerotic lesions [PMID:15129282]. In epithelial tumors, galectin-2 suppresses cell proliferation by inhibiting STAT3 phosphorylation in colorectal cancer and by activating the PI3K/AKT pathway to promote apoptosis in thyroid carcinoma [PMID:33110234, PMID:36221286]. In the tumor microenvironment, tumor cell-derived galectin-2 promotes M2-like macrophage polarization through the CSF1/CSF1R axis, creating an immunosuppressive milieu that can be reversed by inhibitory antibody blockade [PMID:35767614].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Mapping LGALS2 to chromosome 22q12-q13, clustered with LGALS1, established the genomic context of the galectin-2 locus and suggested evolutionary duplication of lactose-binding lectins.\",\n      \"evidence\": \"Chromosomal mapping in human cells\",\n      \"pmids\": [\"8449510\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No functional characterization of the gene product at this stage\",\n        \"Regulatory elements controlling LGALS2 expression not defined\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrating that galectin-2 directly binds LTA and that an LGALS2 promoter SNP modulates its transcription — thereby altering LTA secretion — established galectin-2 as a functional mediator of inflammatory signaling in atherosclerosis.\",\n      \"evidence\": \"Protein binding assay, transcriptional reporter assay, immunohistochemistry of atherosclerotic plaques\",\n      \"pmids\": [\"15129282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of the galectin-2/LTA interaction not resolved\",\n        \"Whether galectin-2 modulates LTA signaling in non-vascular inflammatory contexts is unknown\",\n        \"Downstream signaling consequences beyond LTA secretion not mapped\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying galectin-2 as a suppressor of STAT3 phosphorylation in colorectal cancer — via CRISPR screens, knockout mice, and overexpression — revealed a tumor-suppressive mechanism distinct from its inflammatory role.\",\n      \"evidence\": \"Genome-wide CRISPR knockout screen, Lgals2-KO mouse AOM/DSS model, overexpression in colon tumor cells with pSTAT3 Western blot\",\n      \"pmids\": [\"33110234\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct molecular target through which galectin-2 inhibits STAT3 phosphorylation is unidentified\",\n        \"Whether the carbohydrate-binding activity of galectin-2 is required for STAT3 suppression is untested\",\n        \"Findings from a single laboratory\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Two studies expanded galectin-2's roles in cancer: one showed it suppresses thyroid carcinoma proliferation via PI3K/AKT activation and apoptosis induction, while the other demonstrated that tumor-derived galectin-2 drives M2 macrophage polarization through CSF1/CSF1R, revealing context-dependent tumor-suppressive versus immunosuppressive functions.\",\n      \"evidence\": \"siRNA/overexpression with xenograft models (thyroid carcinoma); in vivo CRISPR screen with inhibitory antibody blockade (breast cancer)\",\n      \"pmids\": [\"36221286\", \"35767614\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The apparently opposing roles — tumor-cell-intrinsic suppression versus microenvironment immunosuppression — are not mechanistically reconciled\",\n        \"Whether galectin-2 directly binds CSF1 or CSF1R or acts indirectly through transcriptional regulation is unresolved\",\n        \"PI3K/AKT activation promoting apoptosis is atypical and the specific mechanism has not been dissected\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unified model explaining how galectin-2's lectin activity connects its inflammatory (LTA binding), tumor-suppressive (STAT3/PI3K-AKT), and immunomodulatory (CSF1/CSF1R–macrophage polarization) functions is lacking.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural or biochemical study has defined whether the carbohydrate-recognition domain mediates all reported protein interactions\",\n        \"Tissue- and context-specific regulation of LGALS2 expression is poorly characterized\",\n        \"No genetic disease association has been validated beyond the MI susceptibility SNP\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"LTA\",\n      \"CSF1R\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Galectin-2 (LGALS2) is a β-galactoside-binding lectin that functions as an immunomodulatory and tumor-regulatory protein across multiple tissue contexts. It directly binds lymphotoxin-alpha (LTA) in vascular smooth muscle cells and macrophages within atherosclerotic lesions, linking it to inflammatory signaling in myocardial infarction pathogenesis [PMID:15129282]. In colon cancer, galectin-2 suppresses tumor growth by inhibiting STAT3 phosphorylation, as demonstrated by enlarged tumors with elevated phospho-STAT3 in Lgals2-knockout mice [PMID:33110234], while in triple-negative breast cancer it drives an immunosuppressive microenvironment by promoting M2-like macrophage polarization and proliferation through the CSF1/CSF1R axis, and antibody-mediated blockade of LGALS2 reverses this immune evasion and arrests tumor growth [PMID:35767614].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"The first mechanistic link for galectin-2 was established by showing it directly binds lymphotoxin-alpha and that a cis-regulatory SNP modulates LGALS2 transcription, thereby altering LTA secretion and connecting galectin-2 to inflammatory vascular disease.\",\n      \"evidence\": \"Protein–protein binding assay, in vitro transcriptional reporter assay for SNP effect, and immunohistochemistry co-localization in human atherosclerotic lesions\",\n      \"pmids\": [\"15129282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of the galectin-2–LTA interaction is undefined\",\n        \"Whether galectin-2/LTA binding is carbohydrate-dependent or protein–protein mediated is not resolved\",\n        \"Causal role in atherosclerosis progression not tested by genetic intervention in vivo\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A direct tumor-suppressive mechanism was identified: galectin-2 inhibits STAT3 phosphorylation in colonic epithelial cells, and Lgals2-knockout mice develop significantly larger colon tumors with hyperactivated STAT3, establishing galectin-2 as a negative regulator of STAT3 signaling in colorectal tumorigenesis.\",\n      \"evidence\": \"Genome-wide CRISPR screen, Lgals2-knockout mouse model with AOM/DSS-induced tumors, and overexpression/knockdown in human colon cancer cells with phospho-STAT3 readout\",\n      \"pmids\": [\"33110234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether galectin-2 directly binds STAT3 or acts via an upstream mediator is unknown\",\n        \"The opposing effect of Gal2 deficiency in colitis versus tumorigenesis is mechanistically unresolved\",\n        \"Relevance of the LTA-binding function to the colon tumor context not examined\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Two studies expanded the cancer biology of galectin-2 in opposite directions: in triple-negative breast cancer, tumor-derived LGALS2 promotes immunosuppression by driving M2-like macrophage polarization via CSF1/CSF1R signaling, while in papillary thyroid carcinoma, LGALS2 suppresses proliferation and induces apoptosis through PI3K/AKT pathway activation.\",\n      \"evidence\": \"In vivo CRISPR screens in multiple mouse TNBC models with antibody blockade and transcriptomic validation [PMID:35767614]; overexpression/knockdown in PTC cell lines with xenograft confirmation and PI3K/AKT immunoblotting [PMID:36221286]\",\n      \"pmids\": [\"35767614\", \"36221286\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The direct receptor or binding partner mediating CSF1/CSF1R axis activation by galectin-2 is unidentified\",\n        \"PI3K/AKT activation mechanism by galectin-2 in thyroid cancer is characterized only at the pathway level without a defined molecular target\",\n        \"How galectin-2 exerts pro-tumorigenic effects in breast cancer but anti-tumorigenic effects in colon and thyroid cancer is not reconciled\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular basis for galectin-2's context-dependent tumor-promoting versus tumor-suppressive activities remains unresolved, and no unifying model connects its lectin-binding properties to the distinct downstream pathways (STAT3, PI3K/AKT, CSF1/CSF1R) engaged in different tissues.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural data for galectin-2 in complex with any signaling partner\",\n        \"Whether carbohydrate recognition is required for each downstream signaling outcome has not been tested\",\n        \"No integrative study has compared galectin-2 interactomes across tissue types\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 2, 3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"LTA\",\n      \"CSF1R\",\n      \"STAT3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}